ONK Therapeutics
ONK Therapeutics is a company focused on advancing cancer treatments, particularly through the development of natural killer cell therapies and CRISPR-edited cancer cell therapies. They are engaged in collaborations and partnerships to explore innovative immunotherapy solutions for cancer patients.
Industries
Nr. of Employees
small (1-50)
ONK Therapeutics
Patents
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US-10960064-B2
View DetailsModified natural killer cells and natural killer cell lines having increased cytotoxicity
US-10906951-B2
View DetailsMethod of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
US-10799536-B2
View Details
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US-10960064-B2
View DetailsModified natural killer cells and natural killer cell lines having increased cytotoxicity
US-10906951-B2
View DetailsMethod of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
US-10799536-B2
View DetailsProducts
Allogeneic CRISPR-edited NK cell therapy candidates
Program to develop off-the-shelf NK cell therapy candidates engineered using CRISPR for oncology indications.
Allogeneic CRISPR-edited NK cell therapy candidates
Program to develop off-the-shelf NK cell therapy candidates engineered using CRISPR for oncology indications.
Services
Strategic research and development partnerships to co-develop engineered cell-therapy candidates for oncology.
Strategic research and development partnerships to co-develop engineered cell-therapy candidates for oncology.
Expertise Areas
- Natural killer (NK) cell therapy development
- CRISPR gene editing for cell therapies
- Allogeneic/off-the-shelf cell therapy development
- Oncology therapeutic collaborations and licensing
Key Technologies
- Natural killer (NK) cell therapies
- CRISPR gene editing
- Allogeneic cell therapy platforms
- Cell engineering for oncology
News & Updates
Collaboration to develop CRISPR-edited cancer cell therapies, with a pact worth up to $920 million.
Part of their collaboration to explore and develop cancer treatments using CRISPR technology.
An article discussing the trend of cancer deals focusing on natural killer cells, highlighting ONK Therapeutics' role in this field.
Collaboration to develop CRISPR-edited cancer cell therapies, with a pact worth up to $920 million.
Part of their collaboration to explore and develop cancer treatments using CRISPR technology.
An article discussing the trend of cancer deals focusing on natural killer cells, highlighting ONK Therapeutics' role in this field.